Baylor Research Institute - Recruiting 18 years or older. - A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria.
Novartis - Recruiting 1 Month to 17 years. - A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients..
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Yale University - Recruiting 3 Months to 50 years. - De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation.
Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects
Northwestern University - Recruiting 18 years to 80 years. - Prospective, Randomized, Open-Label, Controlled Study to Evaluate the Safety and Efficacy of Intensive Glycemic Control on Outcomes Following Liver Transplantation.
Novartis - Recruiting 18 years or older. - A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants.
Everolimus + reduced tacrolimus; Standard tacrolimus
Washington University School of Medicine - Recruiting 18 years to 70 years. - Prospective Registry Study of Neoadjuvant Chemoradiation in Conjunction With Liver Transplantation for Cholangiocarcinoma With Induction Gemcitabine, Followed by 3D Conformal Radiation With 5-FU as a Radiosensitizer, and Maintenance Xeloda Therapy Until Liver Transplantation.
Domp s.p.a. - Recruiting 18 years to 70 years. - A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation.
University Hospital Regensburg - Recruiting 18 years to 65 years. - Safety and Feasibility of Multipotent Adult Progenitor Cells for Immunomodulation Therapy After Liver Transplantation: A Phase I Study of the MiSOT Study Consortium.
Gilead Sciences - Recruiting 18 years or older. - An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies.
Janssen R&D Ireland - Recruiting 18 years or older. - Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation.
Astellas Pharma Inc - Recruiting 5 years to 16 years. - A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prografr Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagrafr Based Immunosuppressive Regimen, Including a Long-Term Follow-Up.
Seoul National University Hospital - Recruiting 18 years to 80 years. - A Randomized Phase ?, Trial With Sirolimus-containing Versus mTOR-inhibitor Free Immunosuppression in Patients Undergoing Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria.
Immunicum AB - Recruiting 18 years or older. - A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma.
Helsinki University Central Hospital - Recruiting 18 years to 70 years. - Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients.
Seoul National University Hospital - Recruiting 20 years to 70 years. - Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy.